Brown Kevin K, Rajan Sujeet K, Shenoy Padmanabha, Mehta Monali, Lopez Meena, Hegde Rashmi S, Gogtay Jaideep
Department of Medicine National Jewish Health, Denver, CO, USA.
Department of Chest Medicine Bombay Hospital and Medical Research Centre, Bhatia Hospital, Mumbai, India.
Expert Rev Respir Med. 2021 Dec;15(12):1539-1549. doi: 10.1080/17476348.2021.2001331. Epub 2021 Nov 29.
Mycophenolate mofetil (MMF), initially approved to prevent rejection in solid organ allograft, is now being increasingly used for other conditions. Over the last decade, MMF has emerged as a useful therapy for a variety of immune-mediated diseases.
There has been a growing interest in the clinical use of MMF in the treatment of ILDs due to its versatile anti-inflammatory, immunomodulatory, anti-fibrotic and anti-proliferative properties. In this focussed review, we summarize the available literature using the Pubmed, Science Direct and EMBASE databases published until June 2021 on the efficacy and tolerability of MMF in various ILDs.
Other than idiopathic pulmonary fibrosis (IPF) and its broader category of progressive fibrosing ILD, there have been no drugs approved by relevant regulatory agencies for the treatment of the multiple other forms of ILD. Though results are limited, immunosuppressants such as MMF have shown promise as an effective and well-tolerated steroid-sparing agent, providing hope that the limited treatment armamentarium for ILDs can be expanded.
霉酚酸酯（MMF）最初被批准用于预防实体器官移植中的排斥反应，现在越来越多地用于其他病症。在过去十年中，MMF已成为治疗多种免疫介导疾病的有效疗法。
由于其具有多种抗炎、免疫调节、抗纤维化和抗增殖特性，MMF在间质性肺疾病（ILD）治疗中的临床应用受到越来越多的关注。在这篇重点综述中，我们使用截至2021年6月在PubMed、Science Direct和EMBASE数据库上发表的文献，总结了MMF在各种ILD中的疗效和耐受性。
除特发性肺纤维化（IPF）及其更广泛的进行性纤维化ILD类别外，尚无相关监管机构批准用于治疗多种其他形式ILD的药物。尽管结果有限，但MMF等免疫抑制剂已显示出作为一种有效且耐受性良好的类固醇替代药物的前景，为扩大ILD有限的治疗手段带来了希望。
